AKBA — Akebia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517022 ·
Last close
$0.81
Market Cap
$225.79M
52W High
$3.20
52W Low
$0.81
ADV30
7,541,489
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 49,128,000 | 38,704,000 | -4,381,000 | -8,908,000 | 349,658,000 | 155,548,000 | 324,640,000 |
| Mar 2026 | 53,544,000 | 41,254,000 | -4,696,000 | -9,054,000 | 362,520,000 | 162,644,000 | 335,145,000 |
| Dec 2025 | 57,622,000 | 45,087,000 | -8,553,000 | -12,244,000 | 376,565,000 | 184,844,000 | 343,955,000 |
| Sep 2025 | 58,766,000 | 49,383,000 | 4,449,000 | 540,000 | 364,152,000 | 166,444,000 | 322,560,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$41,552,000
Investing CF
$-12,095,000
Financing CF
$-11,199,000
CapEx
$-12,095,000
Dividends Paid
—
Buybacks
$-63,000
EPS Diluted TTM
$-0.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,701,667,000
Inventory
$13,018,000
Receivables
$53,506,000
ST Investments
—
EBIT TTM
$-10,509,000
Pretax Income TTM
$-27,846,000
Interest Exp TTM
$17,337,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$219,060,000
EBITDA
$-4,296,000
Free Cash Flow
$33,636,376
Enterprise Value
$307,362,016
Total Cash
$155,548,000
Total Debt
$199,188,000
Shares Out
277,106,245
Trailing EPS
$-0.12
Book Value
$0.09
ROE
-109.4%
ROA
-1.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 236,196,000 | 23,499,000 | -5,345,000 | 376,565,000 | 343,955,000 | 32,610,000 | 67,992,000 |
| Dec 2024 | 160,180,000 | -50,414,000 | -69,410,000 | 220,670,000 | 269,855,000 | -49,185,000 | -40,659,000 |
| Dec 2023 | 194,623,000 | -46,075,000 | -51,925,000 | 241,703,000 | 272,287,000 | -30,584,000 | -23,384,000 |
| Dec 2022 | 292,484,000 | -64,846,000 | -94,226,000 | 356,054,000 | 350,824,000 | 5,230,000 | -73,154,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$232,404,000
NetIncome TTM
$-20,511,000
OpCashFlow TTM
—
Assets (Latest)
$362,520,000
Forward EPS
$-0.36
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.81 · call volume: 15 · put volume: 59
Expected Move to 2027-01-15:
±$0.30
(36.81%) —
implied range
$0.51 –
$1.11
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IFRX | InflaRx N.V. | $225.47M | $1.53 | — |
| MGNX | MACROGENICS INC | $226.14M | $3.55 | — |
| GLSI | Greenwich LifeSciences, Inc. | $222.23M | $15.14 | — |
| PRQR | ProQR Therapeutics N.V. | $221.56M | $1.57 | — |
| SLGL | Sol-Gel Technologies Ltd. | $230.29M | $70.34 | — |
News headlines (Yahoo Finance, 1h cache)
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
2026-10-07 12:00 · Yahoo
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
2026-10-06 12:00 · Yahoo
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
2026-09-14 12:00 · Yahoo
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:05 · Yahoo
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
2026-09-01 12:00 · Yahoo
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...
2026-08-06 05:10 · Yahoo
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
2026-08-05 22:10 · Yahoo
Akebia Therapeutics Q2 Earnings Call Highlights
2026-08-05 22:03 · Yahoo
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-07-29 12:00 · Yahoo
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
2026-06-30 13:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.